Who
Thomas Trimarchi
President and CFO
Company insider
Files Form 4 as: President and CFO, BridgeBio Pharma.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $7.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Aug 2024
- Last trade
- 16 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Aug 2026filed 18 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.8M22,781 at $79.86 | filing |
| 16 Aug 2026filed 18 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.8M22,781 at $79.86 | filing |
| 18 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $678K10,456 at $64.82 | filing |
| 18 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $211K3,195 at $65.95 | filing |
| 18 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $678K10,456 at $64.82 | filing |
| 18 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $211K3,195 at $65.95 | filing |
| 16 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.5M22,781 at $66.13 | filing |
| 16 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.5M22,781 at $66.13 | filing |
| 18 Mar 2026filed 20 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —59,041 at $0.00 | filing |
| 18 Mar 2026filed 20 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —59,041 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.0M13,400 at $74.71 | filing |
| 17 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $15K200 at $75.38 | filing |
| 17 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.0M13,400 at $74.71 | filing |
| 17 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $15K200 at $75.38 | filing |
| 16 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.4M18,819 at $75.25 | filing |
| 16 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.4M18,819 at $75.25 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.0M13,826 at $75.15 | filing |
| 17 Nov 2025filed 18 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $660K9,978 at $66.19 | filing |
| 17 Nov 2025filed 18 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $465K6,956 at $66.84 | filing |
| 16 Nov 2025filed 18 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $1.4M21,317 at $66.39 | filing |
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Thomas Trimarchi; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.